The field’s use of the term “mesenchymal” for one of the glioblastoma molecular subtypes may also encourage a potentially inappropriate tendency to view different subtypes, defined based on large numbers of transcriptomic features, as readily interconvertible in an analogous fashion to EMT in carcinoma cells, where acute exogeneous treatments of growth factors (e.g., TGFβ) drive clear phenotypic changes [46, 47]. This evidence concerns the gene TGFB1 and glioblastoma.